{"url_path":"/sec/qncx/8-k/2026-05-18/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1662774/0001193125-26-228956-index.html","accession_number":"0001193125-26-228956","cik":"0001662774","ticker":"QNCX","issuer_name":"Quince Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1662774/0001193125-26-228956-index.html","primary_entity_key":"0001662774","primary_entity_name":"Quince Therapeutics, Inc."},"word_count":80,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\nNumber\n\n  \n\nTitle\n\n99.2\n  \n[Press Release issued on May 18, 2026](d135388dex992.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nQuince Therapeutics, Inc.\n\n \n\n \nBy:\n \n\n/s/ Dirk Thye\n\nDate: May 18, 2026\n \n\n \nName:\n \nDirk Thye\n\n \n\n \nTitle:\n \nChief Executive Officer"}